🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 167 of 857 · Phase 3 first, then by program name

  1. SUBOXONE

    Indivior Pty Ltd

    Opioid Dependence

    phase 3 small molecule completed

    1 trial

  2. SUBOXONE sublingual film

    Indivior Pty Ltd

    Opioid Use Disorder

    phase 3 small molecule completed

    1 trial

  3. SUZ

    Vertex Pharmaceuticals (Australia) Pty.

    Acute Pain

    phase 3 small molecule completed

    1 trial

  4. SV-BR-1-GM

    BriaCell Therapeutics

    Breast Cancer

    phase 3 mab active

    2 trials

  5. SYLVANT 400 mg powder for concentrate for solution for infusion, ABIRATERONE ACETATE, AMG 509, ABIRATERONE ACETATE, ENZALUTAMIDE, AMG 509, AMG 509, CABAZITAXEL

    Amgen

    Metastatic castration-resistant prostate cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  6. SYR-322-MET

    Takeda

    Clinical Pharmacology

    phase 3 small molecule completed

    1 trial

  7. SYR-472

    Takeda

    Diabetes Mellitus

    phase 3 small molecule completed

    5 trials

  8. SYR-472

    Takeda

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  9. Sabin Strain Inactivated Poliovirus Vaccine

    Sinovac Research and Development Co.,

    Poliomyelitis

    phase 3 mab completed

    1 trial

  10. Sacituzumab Govitecan-hziy

    Gilead Sciences Ireland UC

    Triple Negative Breast Cancer

    phase 3 small molecule active

    1 trial

  11. Sacituzumab tirumotecan

    Merck KGaA, Darmstadt, Germany

    Non-small Cell Lung Cancer (NSCLC)

    phase 3 mab active

    2 trials

  12. Sacituzumab tirumotecan

    Merck KGaA, Darmstadt, Germany

    Breast Neoplasms

    phase 3 small molecule active

    1 trial

  13. Sacituzumab tirumotecan

    Merck KGaA, Darmstadt, Germany

    Non Small Cell Lung Cancer

    phase 3 mab active

    1 trial

  14. Sacubitril-Valsartan

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    STEMI

    phase 3 small molecule active

    1 trial

  15. Safinamide 100 mg PLACEBO: Safinamide 100 mg PLACEBO film-coated tablets have the same composition as the relevant Investigational Medicinal Products except for the presence of Active Substance that is missing in the placebo formulations. The missing amount of active substance Safinamide methanesulfonate is replaced in the PLACEBO formulation with the same amount of Microcrystalline cellulose, one of the excipients already present in the authorised formulation, Xadago 100 mg film-coated tablets, Xadago 50 m

    Verona Pharma Ireland Limited

    PARKINSON’S DISEASE WITH MOTOR FLUCTUATIONS

    phase 3 small molecule active

    1 trial

  16. Salbutamol Aldo-Unión 100 microgramos/dosis suspensión para inhalación en envase a presión, Inhalation powder with lactose monohydrate and magnesium stearate, BREO ELLIPTA, Fluticasone furoate and Vilanterol inhalation powder 100 mcg/25 mcg

    Sandoz Pty Ltd

    Asthma

    phase 3 small molecule active

    1 trial

  17. Salbutamol HFA-134a

    GlaxoSmithKline

    Asthma

    phase 3 small molecule completed

    1 trial

  18. Saline (0.9%, sterile, for infusion)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pneumocystis Jiroveci Pneumonia

    phase 3 small molecule active

    1 trial

  19. Saline Solution Basi 9 mg/ml solution for infusion, Felzartamab

    Biogen

    Kidney Transplant Recipients with Late Antibody-Mediated Rejection

    phase 3 small molecule active

    1 trial

  20. Saline, 0.9% Sodium Chloride Solution for Injection, JNJ-80202135, JNJ-80202135

    Janssen-Cilag International N.V.

    Hemolytic Disease of the Fetus and Newborn (HDFN)

    phase 3 small molecule active

    1 trial

  21. Saline, 0.9% Sodium Chloride Solution for Injection, JNJ-80202135, JNJ-80202135

    Janssen-Cilag International N.V.

    Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

    phase 3 small molecule active

    1 trial

  22. Saline, 0.9% sodium chloride solution IV infusion marketed authorized will be used as the placebo and will be supplied by the site. the SmPC previously authorized are Country specific. for Belgium, Spain and Sweden per local requirements under CTDs no SmPCs were submitted., Delandistrogene moxeparvovec-rokl

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 3 small molecule active

    1 trial

  23. SanaCutan® Basiscreme

    Alphapharm Pty Ltd

    Children with a high risk of developing atopic dermatitis

    phase 3 small molecule active

    1 trial

  24. Saphnelo 300 mg concentrate for solution for infusion, Anifrolumab Placebo

    AstraZeneca AB

    Active Proliferative Lupus Nephritis

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources